Clear Street Lifts Price Target on Editas (EDIT) Medicine Amid Pipeline Progress

Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to $4.60 from $4.00, while maintaining a Buy rating. The firm highlighted the company’s extended cash runway into the third quarter of 2027, supported by recent fundraising, and reaffirmed confidence in Editas’ lead program EDIT‑401, a gene editing therapy targeting LDL cholesterol.

Clear Street Lifts Price Target on Editas Medicine Amid Pipeline Progress

Editas strengthened its balance sheet by raising $17.8 million through its ATM (at-the-market) offering in the third quarter and an additional $17.3 million in the fourth quarter, bringing its pro forma cash balance to $183 million. Clear Street noted this runway now extends beyond initial human data for EDIT‑401, providing financial flexibility to advance development milestones.

On the same day, Editas reported Q3 2025 results, posting EPS of –$0.28, slightly better than analyst estimates. Revenues rose to $7.5 million from $0.1 million in Q3 2024, driven by milestone recognition under its collaboration with Bristol Myers Squibb. CEO Gilmore O’Neill emphasized progress with EDIT‑401, citing preclinical data presented at AHA and ESGCT showing over 90% LDL cholesterol reduction in non‑human primates.

Editas Medicine (NASDAQ:EDIT) is a pioneering gene editing company focused on developing transformative in vivo therapies using CRISPR technology. Its pipeline includes EDIT‑401, with plans to file for IND/CTA by mid‑2026 and achieve human proof‑of‑concept data by year‑end 2026. The company holds exclusive licenses to the Broad Institute’s Cas12a and Cas9 patent estates, positioning it as a leader in precision gene editing.

While we acknowledge the potential of EDIT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EDIT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best European Bank Stocks to Buy Now and 11 Best Solar Energy Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.